Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales

Andrew Chung  |  

The justices on Friday also agreed to resolve Amgen’s appeal in the same case over whether biosimilar makers must give brand-name manufacturers a copy of their application to make a copycat drug after it is submitted to the FDA.

The case is Sandoz v. Amgen in the Supreme Court of the United States, 15-1039 and Amgen v. Sandoz, 15-1195.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight

    WASHINGTON (Reuters)—The U.S. Supreme Court on Monday declined to hear a case over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval before bringing them to the market. The justices opted not to take up Apotex Inc.’s appeal of a July federal appeals court ruling that could…

    U.S. Supreme Court Speeds Copycat Biologic Drugs to Market

    WASHINGTON (Reuters)—The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9–0 ruling, overturned a lower court…